In gastric cancer cells, GRg3 combined with cisplatin modulates the Wnt/β-catenin signaling pathway, downregulates the expression of pathway-associated proteins (Wnt, β-catenin, C-myc, and cyclin D1) and EMT-associated proteins, significantly inhibits the activity of SGC-7901 cells, increases cisplatin-induced apoptosis, enhances the sensitivity of gastric cancer cells to cisplatin chemotherapy, enhances the efficacy of chemotherapy, and inhibits the malignant progression of tumors (12). The gene discussed is CCND1; the disease is gastric cancer.